Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 686

1.

Yves Vanrenterghem (1948–2013: Belgian giant of organ transplantation).

Kahan BD.

Transplant Proc. 2014 Dec;46(10):3245-6. No abstract available.

PMID:
25650467
2.

Wojciech Rowinski, a humanist and transplant surgeon, played a seminal role to establish the government-run national transplantation program in Poland.

Stepkowski S, Kahan BD.

Transplant Proc. 2014 Jun;46(5):1261-2. doi: 10.1016/j.transproceed.2014.05.002. No abstract available.

PMID:
24935287
3.

Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts.

Khattar M, Deng R, Kahan BD, Schroder PM, Phan T, Rutzky LP, Stepkowski SM.

Transplantation. 2013 Apr 15;95(7):919-27. doi: 10.1097/TP.0b013e3182842396.

4.

Transplantation proceedings--a decade of evolution.

Kahan BD.

Transplant Proc. 2012 Jan;44(1):3-5. doi: 10.1016/j.transproceed.2012.01.002. No abstract available.

PMID:
22310562
6.

Fifty years in the vineyard of transplantation: looking back.

Kahan BD.

Transplant Proc. 2011 Oct;43(8):2853-9. doi: 10.1016/j.transproceed.2011.08.058. Review.

PMID:
21996173
7.

Pharmacology of synergism among immunosuppressive drugs for transplantation.

Kahan BD.

Clin Pharmacol Ther. 2011 Aug;90(2):303-9. doi: 10.1038/clpt.2011.100. Epub 2011 Jun 29. No abstract available.

PMID:
21716275
8.

Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens.

Gyurus E, Kaposztas Z, Kahan BD.

Transplant Proc. 2011 Jun;43(5):1583-92. doi: 10.1016/j.transproceed.2011.05.001.

PMID:
21693238
9.

New-onset diabetes after renal transplantation: diagnosis, incidence, risk factors, impact on outcomes, and novel implications.

Kaposztas Z, Gyurus E, Kahan BD.

Transplant Proc. 2011 Jun;43(5):1375-94. doi: 10.1016/j.transproceed.2011.04.008.

PMID:
21693204
10.

Frontiers in immunosuppression.

Kahan BD.

Transplant Proc. 2011 Apr;43(3):822-5. doi: 10.1016/j.transproceed.2011.02.001.

PMID:
21486607
11.

Forty years of publication of Transplantation Proceedings--the fourth decade: Globalization of the enterprise.

Kahan BD.

Transplant Proc. 2011 Jan-Feb;43(1):3-29. doi: 10.1016/j.transproceed.2010.12.052. No abstract available.

PMID:
21335147
12.

YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.

Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway R, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S.

Clin Transplant. 2011 Jul-Aug;25(4):523-33. doi: 10.1111/j.1399-0012.2010.01295.x. Epub 2010 Jun 22.

PMID:
20573162
13.

Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.

Kahan BD, Benavides C, Schoenberg L, Podbielski J, Green C.

Clin Nephrol. 2010 May;73(5):344-53.

PMID:
20420794
14.

Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.

Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD.

Transplantation. 2010 Mar 27;89(6):727-32. doi: 10.1097/TP.0b013e3181c9dc9b.

PMID:
20195219
15.

mTOR inhibition: the learning curve in kidney transplantation.

Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, Oberbauer R, Kahan BD.

Transpl Int. 2010 May 1;23(5):447-60. doi: 10.1111/j.1432-2277.2010.01051.x. Epub 2010 Feb 3. Review.

16.

Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity.

Fernandes I, Zhang Y, Qi Y, Wang ME, Podder H, Lisik W, Knight R, Kahan BD, Stepkowski SM.

Transplantation. 2009 Dec 27;88(12):1323-31. doi: 10.1097/TP.0b013e3181bd5951.

PMID:
20029328
17.

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.

Transplant Proc. 2009 Dec;41(10):4407-10. doi: 10.1016/j.transproceed.2009.10.005.

PMID:
20005409
18.

Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.

Kahan BD.

Transplant Proc. 2009 Dec;41(10):3975-4020. doi: 10.1016/j.transproceed.2009.10.003. No abstract available.

PMID:
20005335
19.

Current approaches to the use of sirolimus in renal transplantation.

Kahan BD.

Transplant Proc. 2009 Oct;41(8):3011-5. doi: 10.1016/j.transproceed.2009.07.104.

PMID:
19857664
20.

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.

Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Mendez R, Carvalho DB, Shapiro R, Rajagopalan PR, Mayer H, Slade J, Kahan BD; FTY720A2202 clinical study group.

Clin Transplant. 2009 Sep-Oct;23(5):589-99. doi: 10.1111/j.1399-0012.2009.01070.x. Epub 2009 Aug 27.

PMID:
19719728
21.

Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.

Petero VG Jr, Kaposztas Z, Kahan BD.

Clin Transplant. 2010 Mar-Apr;24(2):243-51. doi: 10.1111/j.1399-0012.2009.01055.x. Epub 2009 Aug 19.

PMID:
19694771
22.

Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution.

Kahan BD.

Transplant Proc. 2009 Jun;41(5):1423-37. doi: 10.1016/j.transproceed.2009.05.001. Review.

PMID:
19545653
23.

Sirolimus-based therapy for kidney transplantation from expanded criteria donors.

Rigotti P, Kahan BD.

Transplantation. 2009 Apr 27;87(8 Suppl):S11-3. doi: 10.1097/TP.0b013e3181a058a1.

PMID:
19384180
24.

Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.

Kahan BD.

Transplant Proc. 2008 Dec;40(10 Suppl):S17-20. doi: 10.1016/j.transproceed.2008.10.019. Review.

PMID:
19100899
25.
26.
27.

Impact of rituximab therapy for treatment of acute humoral rejection.

Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, Pollard V, Kahan BD.

Clin Transplant. 2009 Jan-Feb;23(1):63-73. doi: 10.1111/j.1399-0012.2008.00902.x.

PMID:
19200217
28.

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group.

Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.

PMID:
19005398
29.

Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.

Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD.

Clin Transplant. 2008 Sep-Oct;22(5):645-50. doi: 10.1111/j.1399-0012.2008.00839.x. Epub 2008 Jul 24.

PMID:
18657156
30.

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.

Kaposztas Z, Etheridge WB, Kahan BD.

Transplant Proc. 2008 Jun;40(5):1744-6. doi: 10.1016/j.transproceed.2007.11.072.

PMID:
18589184
31.

The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen.

Kahan BD, Podbielski J, Childs B.

Transplant Proc. 2008 Jun;40(5):1429-34. doi: 10.1016/j.transproceed.2008.04.009.

PMID:
18589123
32.

Anesthetic rejection followed by surgical salvage.

Kahan BD, Podder H.

Clin Transpl. 2006:572-3. No abstract available.

PMID:
18365439
33.

Sickle cell disease: a formidable enemy of the transplanter.

Podder H, Kerman RH, Illoh OC, Kahan BD.

Clin Transpl. 2006:570-1. No abstract available.

PMID:
18365438
34.

Frontiers in immunosuppression.

Kahan BD.

Transplant Proc. 2008 Jan-Feb;40(1):11-5. doi: 10.1016/j.transproceed.2007.12.007.

PMID:
18261536
35.

Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.

Burke JT, Brault Y, Kahan BD, Hricik DE, Grinyó JM, Chapman JR, Polinsky M, Neylan JF.

Transpl Int. 2008 May;21(5):434-40. doi: 10.1111/j.1432-2277.2007.00624.x. Epub 2008 Jan 9.

36.

Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.

Lisik W, Schoenberg L, Lasky RE, Kahan BD.

Transplant Proc. 2007 Dec;39(10):3086-92.

PMID:
18089328
37.
38.

[Lymphocele and kidney transplantation].

Langer R, Tóth A, Máthé Z, Remport A, Járay J, Kahan BD.

Orv Hetil. 2007 Aug 5;148(31):1475-80. Hungarian.

PMID:
17656338
39.

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.

Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.

Clin Transplant. 2007 Jul-Aug;21(4):460-5.

PMID:
17645704
40.

BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.

Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD.

Transplantation. 2007 Jul 15;84(1):83-8.

PMID:
17627242
41.

Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations.

Kobayashi K, Censullo ML, Rossman LL, Kyriakides PN, Kahan BD, Cohen AM.

Radiographics. 2007 Jul-Aug;27(4):1109-30. Review.

PMID:
17620470
42.

Losing the kingdom: the case against commercial organ donation.

Kahan BD.

Nat Clin Pract Urol. 2007 Jun;4(6):290-1. No abstract available.

PMID:
17551533
43.

Fokko Johannes van der Woude, 1953-2006.

Kahan BD.

Transplant Proc. 2007 Mar;39(2):321-4. No abstract available.

PMID:
17415942
44.

Transplantation proceedings in the second era: an organ undergoing evolution.

Kahan BD.

Transplant Proc. 2007 Jan-Feb;39(1):5-8. No abstract available.

PMID:
17275464
45.

Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.

Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM; FTY720 Study Group.

Transplantation. 2006 Dec 27;82(12):1689-97.

PMID:
17198261
46.

Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.

Kahan BD, Podbielski J, Schoenberg L.

Transplant Proc. 2006 Nov;38(9):2842-6.

PMID:
17112844
47.

Fibromuscular dysplasia recurrence after kidney transplantation: case report.

Benavides CA, Csapo Z, Timmins K, Holley L, Katz SM, Van Buren CT, Kahan BD.

Clin Nephrol. 2006 Jul;66(1):67-70.

PMID:
16878439
48.

The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?

Knight RJ, Kahan BD.

Kidney Int. 2006 Sep;70(6):994-9. Epub 2006 Jul 26. Review.

49.

Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipients.

Csapo Z, Knight RJ, Podder H, Kerman RH, Schoenberg L, Katz SM, Van Buren CT, Kahan BD.

Clin Transplant. 2006 Jul-Aug;20(4):423-6.

PMID:
16842516
50.

Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine.

Knight RJ, Kerman RH, Zela S, Podbielski J, Podder H, Van Buren CT, Katz S, Kahan BD.

Transplantation. 2006 Apr 27;81(8):1101-5.

PMID:
16641593

Supplemental Content

Loading ...
Support Center